COVID-19 Pandemic Impact at Clinical Sites Delays Study MENLO PARK, Calif., March 30, 2020 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...
– Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis – – Enrollment complete for the pivotal Phase 3 trial of rilonacept in recurrent...
A phase II trial of ficlatuzumab (AV-299), an investigational HGF inhibitory antibody, in patients with relapsed and refractory acute myeloid leukemia (AML) joins the growing list of clinical trials halted due to the coronavirus disease 2019 (COVID-19) pandemic....
Due to the global spread of the Sars-cov-2 virus Cereno Scientific announces that the company will postpone the planned Phase II clinical trial with the company’s lead compound CS1. The start of the study was previously planned for mid-year 2020. Cereno Scientific is...
Atlanta, GA – Emory Healthcare announced that its Vaccine and Treatment Evaluation Unit will be a part of clinical testing a COVID-19 vaccine. “The goals of the Phase I study, which began on March 16 at the VTEU at the Kaiser Permanente Washington Health Research...
CAMBRIDGE, Mass. & BOULDER, Colo.–(BUSINESS WIRE)–Mar. 27, 2020– AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent...
Email
Text